Remdesivir GS-5734 CAS 1809249-37-3 COVID-19 API High Quality
Manufacturer Commercial Supple Remdesivir et intermedia cum High Quality
Remdesivir CAS 1809249-37-3
2-Ethyl-1-butanol CAS 97-95-0
Trimethylsilyl Cyanide CAS 7677-24-9
4-Nitrophenol CAS 100-02-7
2-Ethylbutyl((S)-(perfluorophenoxys)(phosphoryl)-L-alaninatum CAS 1911578-98-7
N-[(S)-(4-nitrophenoxy) phenoxyphosphinyl]-L-Alanine 2-ethylbutyl ester CAS 1354823-36-1
(S)-2-Ethylbutyl 2-Aminopropanoate Hydrochloride CAS 946511-97-3
Remdesivir metabolitae (GS-441524) CAS 1191237-69-0
Remdesivir N-2 Intermedia CAS 1191237-80-5
2,3,5-Tri-O-benzyl-D-ribonolactone CAS 55094-52-5
7-Bromopyrrolo[2,1-f][1,2,4]triazin-4-amine CAS 937046-98-5
Pyrrolo[1,2-F][1,2,4]Triazin-4-Amine CAS 159326-68-8
4-Amino-7-iodopyrrolo[2,1-f][1,2,4]triazine CAS 1770840-43-1
Nomen chemicum | Remdesivir |
Synonyma | GS-5734;2-ethylbutyl((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano -3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninatum |
CAS Number | 1809249-37-3 |
CATTUS Number | RF-API96 |
Stock Status | In Stock, Productio Ascendite usque ad Centum chiliogrammata |
Formulae hypotheticae | C27H35N6O8P |
M. Pondus | 602.58 |
Density | 1.47±0.1 g/cm3 |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | White ad Off-White solidus pulveris |
Lepidium sativum | IR: Imaginum producti effusio ultrarubrum consentaneum esse debet cum substantiae relationis |
Lepidium sativum B * | HPLC retentionis tempus similis referat substantiam |
Imprimis Rotationes | -19.0° ~ -22.0° |
Solubilitas | Solunle in Methanol, Parce Solubile in Ethanol, Paulo solutum in Acetonitrile, In aqua fere Insolubile. |
Substantiae cognatae | |
Omnis immunditia | ≤0.10% |
Totalis immunditias | ≤1.0% |
RD-3.1 | ≤0.10% |
RD-C | ≤0.10% |
RD-D | ≤0.10% |
RD-E | ≤0.10% |
RP-Isomer | ≤0.10% |
Nitrophenol | ≤0.10% |
RELICTUM Solvents | |
Methanolum Dichloride | ≤6000ppm |
Acetone | ≤5000ppm |
Isopropyl Sin | ≤5000ppm |
Acetonitrile | ≤410ppm |
Dichloromethane | ≤600ppm |
Methyl tert Butyl Ether | ≤5000ppm |
Ethyl Acetate | ≤5000ppm |
Tetrahydrofuran | ≤720ppm |
n-Heptane | ≤5000ppm |
Assay | 98.0% ~ 102.0% (Ratio in exaruit basis) |
Summa Aerobic Comites | |
Aerobic Bacteria | ≤100cfu/g* |
Fermentum et Molde | ≤10cfu/g* |
E. Coil | Negative |
Bacterial Endotoxin | ≤1.0EU |
Metalla gravis | ≤20ppm |
Test Standard | Enterprise Standard |
Consuetudinem | API, COVID-19 |
sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.
Remdesivir (CAS 1809249-37-3), sub noto nomine Veklury venditum, est medicamentum latum-spectrum antivirale a comitatu Scientiarum Gilead biopharmaceutico elaboratum.Datur per iniectionem in venam.Per COVID-19 pandemicum, remdesivir probatus est vel auctoritate usus subitis ad COVID-19 tractandum in regionibus circiter 50.Renovatae normae a Mundi Salus Organizatio mense Novembri 2020 includunt commendationem conditionalem contra usum Remdesiviri ad tractandum de COVID-19.Remdesivir principio hepatitis C tractandi elaboravit, et postea de morbis virus virus et Marburg infectio virium Ebola quaesitum est priusquam investigaretur ut curatio post-infectio pro COVID-19.Frequentissimum latus effectus in voluntariis sanis elevatur gradus sanguinis enzymes iecoris (signum problematum iecoris).Frequentissima pars effectuum hominum cum covid-19 nausea est.Effectus latus includere potest iecoris inflammationem et infusionem reactionem relatas cum nausea, pressura sanguinis humilis, et sudore.Remdesivir prodrug intendit ad partum intracellulare GS-441524 permittere monophosphatum et subsequentem biotransformationem in triphosphatum GS-441524, analogum ribonucleotide inhibitoris RNA polymerasi.